Elevated Preoperative Serum CA125 Predicts Larger Tumor Diameter in Patients with Hepatocellular Carcinoma and Low AFP Levels

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2019 Oct 31

PMID 31662990

Citations 6

Authors

Sanshun Zhou

Zusen Wang

Manjiang Li

Liqun Wu

Affiliations

Soon will be listed here.

Abstract

Aim: Little is known about the association between cancer antigen 125 (MUC16/CA125) concentrations and tumor diameter of patients with hepatocellular carcinoma (HCC) and low AFP levels. To fill this gap in our knowledge, we conducted a retrospective study of 427 patients with HCC with AFP ≤200 ng/mL who underwent R0 resection at our center.

Methods: The associations between CA125 concentrations and patients' clinicopathological characteristics were analyzed. Survival vs CA125 levels was also evaluated between patient groups with CA125 ≤30 U/mL or CA125 >30 U/mL. Independent risk factors of disease-free survival (DFS) and overall survival (OS) were analyzed with Cox hazard regression model.

Results: Elevated preoperative serum CA125 was significantly associated with maximal tumor diameter (MTD) >5 cm and female sex ( < 0.001 and =0.044, respectively). The DFS and OS of patients with CA125 ≤30 U/mL ( = 392) were significantly higher compared with those with CA125 >30 U/mL ( = 35) (=0.003 and =0.001 respectively). Multivariate analysis revealed that MTD >5 cm was an independent risk factor of DFS (HR = 1.891, 95% CI: 1.379-2.592, < 0.001) and OS (2.709, 1.848-3.972, < 0.001).

Conclusions: In conclusion, elevated preoperative serum CA125 predicted larger tumor diameter and poor prognosis after patients with HCC with AFP ≤200 ng/mL underwent R0 resection, which may be explained by the elevation of the preoperative serum CA125 level significantly associated with MTD>5 cm.

Citing Articles

CK19 protein expression: the best cutoff value on the prognosis and the prognosis model of hepatocellular carcinoma.

Yang C, Xiang W, Wu Z, Li N, Xie G, Huang J BMC Cancer. 2025; 25(1):55.

PMID: 39789507 PMC: 11720332. DOI: 10.1186/s12885-024-13399-9.

Mucins as Potential Biomarkers for Early Detection of Cancer.

Gautam S, Khan P, Natarajan G, Atri P, Aithal A, Ganti A Cancers (Basel). 2023; 15(6).

PMID: 36980526 PMC: 10046558. DOI: 10.3390/cancers15061640.

Prediction of Survival Prognosis for Spinal Metastasis From Cancer of Unknown Primary: Derivation and Validation of a Nomogram Model.

Yang M, Ma X, Wang P, Yang J, Zhong N, Liu Y Global Spine J. 2022; 14(1):283-294.

PMID: 35615968 PMC: 10676151. DOI: 10.1177/21925682221103833.

Factors associated with serum CA125 level in women without ovarian cancer in the United States: a population-based study.

Hu X, Zhang J, Cao Y BMC Cancer. 2022; 22(1):544.

PMID: 35568827 PMC: 9107191. DOI: 10.1186/s12885-022-09637-7.

Clinical Value Evaluation of microRNA-324-3p and Other Available Biomarkers in Patients With HBV Infection-Related Hepatocellular Carcinoma.

Zhao L, Yang Q, Liu J Open Forum Infect Dis. 2021; 8(6):ofab108.

PMID: 34189151 PMC: 8232384. DOI: 10.1093/ofid/ofab108.

References

Fan K, Yang C, Fan Z, Huang Q, Zhang Y, Cheng H . MUC16 C terminal-induced secretion of tumor-derived IL-6 contributes to tumor-associated Treg enrichment in pancreatic cancer. Cancer Lett. 2018; 418:167-175. DOI: 10.1016/j.canlet.2018.01.017. View

Forner A, Llovet J, Bruix J . Hepatocellular carcinoma. Lancet. 2012; 379(9822):1245-55. DOI: 10.1016/S0140-6736(11)61347-0. View

Fortner R, Schock H, Le Cornet C, Husing A, Vitonis A, Johnson T . Ovarian cancer early detection by circulating CA125 in the context of anti-CA125 autoantibody levels: Results from the EPIC cohort. Int J Cancer. 2017; 142(7):1355-1360. PMC: 5805613. DOI: 10.1002/ijc.31164. View

Bast Jr R, Feeney M, Lazarus H, Nadler L, Colvin R, Knapp R . Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981; 68(5):1331-7. PMC: 370929. DOI: 10.1172/jci110380. View

Schmiegel W, Buchberger B, Follmann M, Graeven U, Heinemann V, Langer T . . Z Gastroenterol. 2017; 55(12):1344-1498. DOI: 10.1055/s-0043-121106. View

Belisle J, Horibata S, Jennifer G, Petrie S, Kapur A, Andre S . Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes. Mol Cancer. 2010; 9:118. PMC: 2890604. DOI: 10.1186/1476-4598-9-118. View

Earl T, Chapman W . Hepatocellular carcinoma: resection versus transplantation. Semin Liver Dis. 2013; 33(3):282-92. DOI: 10.1055/s-0033-1351783. View

Schieving J, de Vries M, van Vugt J, Weemaes C, van Deuren M, Nicolai J . Alpha-fetoprotein, a fascinating protein and biomarker in neurology. Eur J Paediatr Neurol. 2013; 18(3):243-8. DOI: 10.1016/j.ejpn.2013.09.003. View

Dai Y, Chen M, Fan Z, Yan K, Yin S, Zhang X . Diagnosis of small hepatic nodules detected by surveillance ultrasound in patients with cirrhosis: Comparison between contrast-enhanced ultrasound and contrast-enhanced helical computed tomography. Hepatol Res. 2007; 38(3):281-90. DOI: 10.1111/j.1872-034X.2007.00269.x. View

10.

Whiteside T, Mandapathil M, Szczepanski M, Szajnik M . Mechanisms of tumor escape from the immune system: adenosine-producing Treg, exosomes and tumor-associated TLRs. Bull Cancer. 2011; 98(2):E25-31. DOI: 10.1684/bdc.2010.1294. View

11.

Nakao K, Ichikawa T . Recent topics on α-fetoprotein. Hepatol Res. 2013; 43(8):820-5. DOI: 10.1111/hepr.12052. View

12.

Gubbels J, Felder M, Horibata S, Belisle J, Kapur A, Holden H . MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells. Mol Cancer. 2010; 9:11. PMC: 2818693. DOI: 10.1186/1476-4598-9-11. View

13.

Pradjatmo H . Impact of Preoperative Serum Levels of CA 125 on Epithelial Ovarian Cancer Survival. Asian Pac J Cancer Prev. 2016; 17(4):1881-6. DOI: 10.7314/apjcp.2016.17.4.1881. View

14.

Kitamura T, Qian B, Pollard J . Immune cell promotion of metastasis. Nat Rev Immunol. 2015; 15(2):73-86. PMC: 4470277. DOI: 10.1038/nri3789. View

15.

Singhal A, Lander E, Karachristos A, Daly E, Dowling P, Patel V . Elevation of CA 125 and CA 19-9 in patients with end-stage liver disease. Int J Biol Markers. 2012; 27(2):e147-51. DOI: 10.5301/JBM.2012.9139. View

16.

Edula R, Muthukuru S, Moroianu S, Wang Y, Lingiah V, Fung P . CA-125 Significance in Cirrhosis and Correlation with Disease Severity and Portal Hypertension: A Retrospective Study. J Clin Transl Hepatol. 2018; 6(3):241-246. PMC: 6160305. DOI: 10.14218/JCTH.2017.00070. View

17.

Liang C, Qin Y, Zhang B, Ji S, Shi S, Xu W . Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma. Mol Cancer Res. 2017; 15(2):201-212. DOI: 10.1158/1541-7786.MCR-16-0296. View

18.

Zhao L, Xie C, Liu D, Li T, Zhang Y, Wan C . Early Detection of Hepatocellular Carcinoma in Patients with Hepatocirrhosis by Soluble B7-H3. J Gastrointest Surg. 2017; 21(5):807-812. DOI: 10.1007/s11605-017-3386-1. View

19.

Song P, Xia J, Inagaki Y, Hasegawa K, Sakamoto Y, Kokudo N . Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma. World J Gastroenterol. 2016; 22(1):262-74. PMC: 4698491. DOI: 10.3748/wjg.v22.i1.262. View

20.

Roxburgh C, Salmond J, Horgan P, Oien K, McMillan D . The relationship between the local and systemic inflammatory responses and survival in patients undergoing curative surgery for colon and rectal cancers. J Gastrointest Surg. 2009; 13(11):2011-8. DOI: 10.1007/s11605-009-1034-0. View